Pharmaceutical giant Eli Lilly is reportedly nearing a deal to acquire AtaiBeckley, a biotech company specializing in psychedelic-based treatments for mental health. The acquisition could be announced as early as this week, with market speculation suggesting a purchase price at a significant premium to AtaiBeckley's current market value, which stands at approximately $2 billion. Following news of the potential acquisition, AtaiBeckley's shares soared, experiencing a 66% jump in aftermarket trading and a 31% increase year-to-date.
This proposed acquisition highlights Eli Lilly's strategic expansion into neuroscience, moving beyond its dominant obesity and diabetes franchises. AtaiBeckley's most promising candidate, BPL-003, is an intranasal formulation of 5-MeO-DMT designed for treatment-resistant depression. This drug has received Breakthrough Therapy designation from the U.S. Food and Drug Administration due to its rapid-acting effects, which can provide improvement within two days, a significant advantage over traditional antidepressants like Prozac that can take weeks to show efficacy.
The deal signals a growing interest from major pharmaceutical companies in the psychedelic medicine sector. Eli Lilly, having been behind the launch of Prozac in the late 1980s, is now looking to integrate faster-acting solutions into its psychiatric medicine portfolio. The success of Johnson & Johnson's psychedelic-derived nasal spray, Spravato, has demonstrated a viable commercial model for such treatments, further validating the market for rapid-onset mental health therapies.
